Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,387,222 papers from all fields of science
Search
Sign In
Create Free Account
trebananib
Known as:
trenananib
An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. AMG 386 targets and binds to Ang1 and Ang2, thereby…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (1)
AMG 386
Broader (3)
Angiogenesis Inhibitors
Pharmacologic Substance
Recombinant Fusion Proteins
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Assessing the Benefit of Trebananib in Advanced Ovarian Cancer
D. Levitan
2019
Corpus ID: 181998412
Researchers tested the angiogenesis inhibitor trebananib combined with the standard of care in patients with advanced ovarian…
Expand
Review
2017
Review
2017
Chapter 3 Antiangiogenic Therapy in Epithelial Ovarian Cancer
M. Bermejo
,
L. Iglesias
,
M. E. López
,
A. Montes
,
J. G. Mata
2017
Corpus ID: 38458466
Approximately 75% of women with ovarian cancer are diagnosed at advanced stages (FIGO stage III/IV), with 15-23 months median…
Expand
2017
2017
First-Line Systemic Therapy (Chemo/Antiangiogenics)
S. Pignata
,
S. Cecere
2017
Corpus ID: 79066414
Epithelial ovarian cancer (EOC) is often diagnosed in advanced stage. Optimal cytoreductive surgery followed by a platinum–taxane…
Expand
Review
2016
Review
2016
Antiangiogenic Therapy in Epithelial Ovarian Cancer
M. Bermejo
,
L. I. Rey
,
M. E. López
,
A. Montes
,
J. G. Mata
2016
Corpus ID: 74398900
Approximately 75% of women with ovarian cancer are diagnosed at advanced stages (FIGO stage III/IV), with 15-23 months median…
Expand
2015
2015
Kidney cancer: Trebananib plus sunitinib improves survival outcomes
Nature reviews. Urology
2015
Corpus ID: 23554455
2015
2015
ENGOT-OV-6/TRINOVA-2: RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN PLUS TREBANANIB OR PLACEBO IN WOMEN WITH RECURRENT PARTIALLY PLATINUM-SENSITIVE OR RESISTANT OVARIAN…
Christian Marth
,
I. Vergote
,
+17 authors
S. Altintas
2015
Corpus ID: 263475088
2014
2014
Anti-Angiogenese mit Trebananib
C. Berndt
Info Onkologie
2014
Corpus ID: 70631135
US-Onkologen haben im Blut von Männern mit einem metastasierten Prostatakarzinom einen RNA-Marker iden ti ziert, der eng mit…
Expand
2014
2014
Angio-Inhibitors in Ovarian Cancer
N. Gavalas
,
S. Trachana
,
M. Dimopoulos
,
A. Bamias
2014
Corpus ID: 57789828
Ovarian Cancer represents the most fatal type of gynaecological malignancies. The tumor microenvironment consists the region…
Expand
Review
2014
Review
2014
Trebananib: an alternative anti-angiogenic strategy
J. West
2014
Corpus ID: 74660823
So far, the only study to show a signifi cant overall survival benefi t was the ICON6 study, 7 in which patients with platinum…
Expand
2013
2013
Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer
B. Gillis
2013
Corpus ID: 78783785
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE